Trial Profile

A phase 2b clinical trial of Xiflam in Geographic Atrophy (GA)

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 12 Oct 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tonabersat (Primary)
Indications Dry macular degeneration
Focus Therapeutic Use
Sponsors InflammX

Most Recent Events

12 Oct 2022 New trial record
29 Sep 2022 According to an InflammX Therapeutics media release, the study is planned to commence by year end 2022.
29 Sep 2022 According to an InflammX Therapeutics media release, the company has submitted an IND amendment to the US FDA to initiate the trial.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com